144 related articles for article (PubMed ID: 12798084)
1. The malaria vaccine development program in Papua New Guinea.
Genton B; Anders RF; Alpers MP; Reeder JC
Trends Parasitol; 2003 Jun; 19(6):264-70. PubMed ID: 12798084
[TBL] [Abstract][Full Text] [Related]
2. Towards a malaria vaccine for Papua New Guinea.
Reeder JC
P N G Med J; 2001; 44(1-2):17-23. PubMed ID: 12418674
[TBL] [Abstract][Full Text] [Related]
3. Health research in Papua New Guinea.
Reeder JC
Trends Parasitol; 2003 Jun; 19(6):241-5. PubMed ID: 12798079
[TBL] [Abstract][Full Text] [Related]
4. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
Genton B; Betuela I; Felger I; Al-Yaman F; Anders RF; Saul A; Rare L; Baisor M; Lorry K; Brown GV; Pye D; Irving DO; Smith TA; Beck HP; Alpers MP
J Infect Dis; 2002 Mar; 185(6):820-7. PubMed ID: 11920300
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for preventing malaria (blood-stage).
Graves P; Gelband H
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006199. PubMed ID: 17054281
[TBL] [Abstract][Full Text] [Related]
6. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies.
Alpers MP; al-Yaman F; Beck HP; Bhatia KK; Hii J; Lewis DJ; Paru R; Smith TA
P N G Med J; 1992 Dec; 35(4):285-97. PubMed ID: 1341090
[TBL] [Abstract][Full Text] [Related]
7. Engaging the community in research: lessons learned from the malaria vaccine trial.
Reeder JC; Taime J
Trends Parasitol; 2003 Jun; 19(6):281-2. PubMed ID: 12798087
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Global Fund-supported National Malaria Control Program in Papua New Guinea, 2009-2014.
Hetzel MW; Pulford J; Maraga S; Barnadas C; Reimer LJ; Tavul L; Jamea-Maiasa S; Tandrapah T; Maalsen A; Makita L; Siba PM; Mueller I
P N G Med J; 2014; 57(1-4):7-29. PubMed ID: 26930885
[TBL] [Abstract][Full Text] [Related]
9. Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum.
Chauhan VS; Yazdani SS; Gaur D
Hum Vaccin; 2010 Sep; 6(9):. PubMed ID: 20861668
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
11. Vaccines against malaria: perspectives from Papua New Guinea.
Mueller I; Genton B; Betuela I; Alpers MP
Hum Vaccin; 2010 Jan; 6(1):17-20. PubMed ID: 20173407
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
al-Yaman F; Genton B; Anders R; Taraika J; Ginny M; Mellor S; Alpers MP
Parasite Immunol; 1995 Sep; 17(9):493-501. PubMed ID: 8552419
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
Genton B; Al-Yaman F; Betuela I; Anders RF; Saul A; Baea K; Mellombo M; Taraika J; Brown GV; Pye D; Irving DO; Felger I; Beck HP; Smith TA; Alpers MP
Vaccine; 2003 Dec; 22(1):30-41. PubMed ID: 14604568
[TBL] [Abstract][Full Text] [Related]
14. Malaria vaccines: from the laboratory to the field.
Genton B; Corradin G
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Oct; 2(3):255-67. PubMed ID: 12476490
[TBL] [Abstract][Full Text] [Related]
15. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area.
al-Yaman F; Genton B; Taraika J; Anders R; Alpers MP
Parasite Immunol; 1997 Jun; 19(6):249-54. PubMed ID: 9364554
[TBL] [Abstract][Full Text] [Related]
16. Plasmodium falciparum: distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea.
Cortés A; Mellombo M; Benet A; Lorry K; Rare L; Reeder JC
Exp Parasitol; 2004; 106(1-2):22-9. PubMed ID: 15013785
[TBL] [Abstract][Full Text] [Related]
17. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
18. Robert Koch redux: malaria immunology in Papua New Guinea.
Stanisic DI; Mueller I; Betuela I; Siba P; Schofield L
Parasite Immunol; 2010 Aug; 32(8):623-32. PubMed ID: 20626817
[TBL] [Abstract][Full Text] [Related]
19. Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region.
Mueller I; Vantaux A; Karl S; Laman M; Witkowski B; Pepey A; Vinit R; White M; Barry A; Beeson JG; Robinson LJ
Am J Trop Med Hyg; 2022 Oct; 107(4_Suppl):131-137. PubMed ID: 36228917
[TBL] [Abstract][Full Text] [Related]
20. Heritability and segregation analysis of immune responses to specific malaria antigens in Papua New Guinea.
Stirnadel HA; Beck HP; Alpers MP; Smith TA
Genet Epidemiol; 1999; 17(1):16-34. PubMed ID: 10323182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
